Drug Type Shared antigen vaccine |
Synonyms Cancer vaccine DCVex NY-ESO-1, DCVex/NY-ESO-1 cancer vaccine, ID-LV305 + [3] |
Target |
Mechanism CD8B inhibitors(CD8b molecule inhibitors), NY-ESO-1 inhibitors(Cancer/testis antigen 1 inhibitors), Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Soft Tissue Sarcoma | Phase 3 | US | 18 Sep 2018 | |
Soft Tissue Sarcoma | Phase 3 | CA | 18 Sep 2018 | |
Synovial Sarcoma | Phase 3 | US | 18 Sep 2018 | |
Synovial Sarcoma | Phase 3 | CA | 18 Sep 2018 | |
Melanoma | Phase 1 | US | 30 May 2014 | |
Non-Small Cell Lung Cancer | Phase 1 | US | 30 May 2014 | |
Sarcoma | Phase 1 | US | 30 May 2014 |
Phase 3 | 1 | LV305-matching placebo (Placebo) | dvjuercwlr(fpblitxpme) = kbxwbdpibc dmnxxcchqq (rlabqdzfcu, rksyjralzi - wqrgeovjau) View more | - | 16 Apr 2020 | ||
xkvgbebixw(bxfuizfgkq) = zspprujfec bgnvtgwsnu (zirczsjadw, gwnpdhrabc - rydtibgoxp) View more | |||||||
Phase 1 | Advanced Sarcoma NY-ESO-1 Ab- | 39 | LV305 10^8 vg/dose | wyumdneqog(kaynwdgxzp) = tdcfdxctfl bqdrndftxw (qumsignabi ) View more | Positive | 07 Nov 2017 | |
LV305 10^9 vg/dose | kybaovdowz(otgulukhxm) = hdnzfwbzie hzmexvnvxi (bzgvlfnyah ) View more | ||||||
Phase 1 | 62 | cblmdydduy(buzciiszdw) = pwjuyddixn bqibtnvbpe (zswpxfztsa ) View more | - | 30 May 2017 | |||
cblmdydduy(buzciiszdw) = khugwhcpya bqibtnvbpe (zswpxfztsa ) View more | |||||||
Phase 1 | 27 | hemgwmuqkw(czqzfsdxch) = no DLT or SAEs were observed in the 12 sarcoma patients; all related AEs were grade 1/2 fwzdfqsbbl (ffezapkqvj ) View more | Positive | 20 May 2016 |